Albert Bourla· @AlbertBourla · X·· 2026-06-08精选AI 评分60
AI 导读
辉瑞针对血友病A和B型的疗法获FDA批准用于两个新患者人群，为6至11岁伴有抑制物的B型血友病儿童提供首个皮下非因子治疗。辉瑞CEO Albert Bourla表示，该批准使辉瑞的科学能够覆盖更多此前选择有限的患者，尤其是年幼儿童。
推荐理由
辉瑞血友病疗法获FDA批准新增两个患者人群，读者可了解儿童B型血友病伴抑制物患者的首个皮下非因子治疗选择。
正文
Hemophilia has long been one of medicine's great challenges, and for some patients, like young children, the right options have been limited. I am proud that @Pfizer’s science can now reach more of them. Grateful to our researchers and patient community who helped make it possible.
Pfizer’s treatment for #hemophilia A & B received @US_FDA approval for two new patient populations, meeting a significant medical need and offering the first subcutaneous non-factor therapy for children ages 6-11 years old with hemophilia B with inhibitors. Learn more: https://on.pfizer.com/4uVvDgi在 X 查看被引用的帖子
来源：Albert Bourla · x.com